Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.
暂无分享,去创建一个
M. Liedtke | H. Kantarjian | G. Martinelli | E. Jabbour | W. Stock | D. DeAngelo | S. O'brien | A. Advani | E. Vandendries | N. Gökbuget | M. Stelljes | D. Laird | Tao Wang | A. Neuhof